GC Green Cross and Imetas Join Hands for Joint Research on Autoimmune Disease mRNA Therapeutics

GC Green Cross announced on the 12th that it has signed a joint research and development agreement with Imetas Therapeutics for messenger RNA (mRNA) therapeutics related to autoimmune diseases.

GC Green Cross Headquarters. [Photo by GC Green Cross]

Through this joint research, the two companies will develop autoimmune disease treatments by utilizing Imetas' proprietary platform for innate immunity and chronic inflammation regulation, combined with GC Green Cross's mRNA therapeutics and lipid nanoparticle (LNP) delivery platform.

Imetas is a bio-venture based in New Jersey, USA, developing treatments for aging-related cancers and inflammatory diseases by regulating the innate immune system. Based on new evidence that chronic inflammation related to aging is a major mechanism causing autoimmune diseases, the company is developing a novel approach to autoimmune disease treatment through inflammation regulation.

Jae-wook Jung, head of research and development (R&D) at Green Cross, said, "We expect to create significant synergy in developing autoimmune disease treatments through the expertise held by both companies."

Jin Wang, CEO of Imetas, stated, "We anticipate that by utilizing the mRNA platform established by GC Green Cross, we can present new possibilities for treating autoimmune diseases."

This content was produced with the assistance of AI translation services.